Strides Pharma Science has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for sevelamer carbonate for oral suspension USP, 0.8g and 2.4g, from the United States Food & Drug Administration (FDA).
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Renvela for oral suspension, 0.8g and 2.4g of Genzyme. The approval completes the company's sevelamer carbonate portfolio.
The company has 280 cumulative ANDA filings (including the recently acquired portfolio from Endo at Chestnut Ridge) with US FDA, of which 260+ ANDAs have been approved. The company has set a target to launch ~ 60 new products over three years in the US.
Sevelamer carbonate for oral suspension is a medication used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease. When consumed after a meal, the medication binds to dietary phosphate and prevents its absorption thereby managing overall phosphate levels in the blood.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!